Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 9/2018

01-09-2018 | Technical Note

90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material

Authors: I. Kurilova, R. G. H. Beets-Tan, G. A. Ulaner, F. E. Boas, E. N. Petre, H. Yarmohammadi, E. Ziv, A. R. Deipolyi, L. A. Brody, M. Gonen, Constantinos T. Sofocleous

Published in: CardioVascular and Interventional Radiology | Issue 9/2018

Login to get access

Abstract

Objectives

To assess safety and efficacy of 90Y resin microspheres administration using undiluted non-ionic contrast material (UDCM) {100% Omnipaque-300 (Iohexol)} in both the “B” and “D” lines.

Materials and methods

We reviewed all colorectal cancer liver metastases patients treated with 90Y resin microspheres radioembolization (RAE) from 2009 to 2017. As of April 2013, two experienced operators started using UDCM (study group) instead of standard sandwich infusion (control group). Occurrence of myelosuppression (leukopenia, neutropenia, erythrocytopenia or/and thrombocytopenia), stasis, nontarget delivery (NTD), median fluoroscopy radiation dose (FRD), median infusion time (IT), liver progression-free (LPFS) and overall survivals (OS) was evaluated. Complications within 6 months post-RAE were reported according to CTCAE v3.0 criteria.

Results

Study and control groups comprised 23(28%) and 58(72%) patients, respectively. Median follow-up was 9.1 months. There was no statistically significant difference in myelosuppression incidence within 6 months post-RAE between groups. Median FRD and IT for study and control groups were 44.6 vs. 97.35 Gy/cm2 (p = 0.048) and 31 vs. 39 min (p = 0.006), respectively. A 38% lower stasis incidence in study group was not significant (p = 0.34). NTD occurred in 1/27(4%) study vs. 5/73(7%) control group procedures (p = 1). Grade 1–2 and grade 3–4 toxicities between study and control group patients were 36%(8/22) vs. 45%(26/58), p = 0.61 and 9%(2/22) vs. 16%(9/58), p = 0.72, respectively. There was no difference in LPFS and OS between groups.

Conclusion

Administration of 90Y resin microspheres using UDCM in both lines is safe and effective, resulting in lower fluoroscopy radiation dose and shorter infusion time, without evidence of myelosuppression or increased stasis incidence.
Appendix
Available only for authorised users
Literature
1.
Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehen Cancer Netw JNCCN. 2017;15(3):370–98.CrossRef
2.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(8):1386–422.CrossRef
3.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23.CrossRefPubMed
4.
Sotirchos VS, Petre EN, Brown KT, Brody LA, D’Angelica MI, DeMatteo RP, et al. Safe and successful yttrium-90 resin microsphere radioembolization in a heavily pretreated patient with chemorefractory colorectal liver metastases after biliary stent placement above the Papilla. Case Rep Hepatol. 2014;2014:921406.
5.
Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13(1):27–36.CrossRefPubMed
6.
Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(23):3687–94.CrossRef
7.
Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.CrossRefPubMed
8.
Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol Off J Eur Soc Med Oncol. 2001;12(12):1711–20.CrossRef
9.
Sharma RA, Wasan HS, Hazel GAV, Heinemann V, Sharma NK, Taieb J, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol 2017;35(15 suppl):3507
10.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.CrossRefPubMed
11.
Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(9):1099–106.CrossRef
12.
Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19(4):951–9.CrossRefPubMed
13.
Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324–31.CrossRefPubMedPubMedCentral
14.
Paprottka KJ, Todica A, Ilhan H, Rubenthaler J, Schoeppe F, Michl M, et al. Evaluation of Visualization using a 50/50 (contrast media/glucose 5% solution) technique for radioembolization as an alternative to a standard sandwich technique. Cardiovasc Interv Radiol. 2017;40(11):1740–7.CrossRef
15.
SIR-Spheres® Y-90 resin microspheres Package Insert. [.
16.
Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015;14(4):296–305.CrossRefPubMedPubMedCentral
17.
Piana PM, Bar V, Doyle L, Anne R, Sato T, Eschelman DJ, et al. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB Off J Int Hepato Pancreato Biliary Assoc. 2014;16(4):336–41.CrossRef
18.
Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vascul Interv Radiol JVIR. 2005;16(7):937–45.CrossRef
19.
Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology. 1982;142(3):783–6.CrossRefPubMed
20.
Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, et al. Intra-arterial treatment with (9)(0)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging. 2011;38(12):2117–24.CrossRefPubMed
21.
22.
Sirtex Medical Ltd. Technical Bulletin, August 7, 2013. Available from Sirtex Medical
23.
Chao C, Stavropoulos SW, Mondschein JI, Dagli M, Sudheendra D, Nadolski G, et al. Effect of Substituting 50% isovue for sterile water as the delivery medium for SIR-Spheres: improved dose delivery and decreased incidence of stasis. Clin Nucl Med. 2017;42(3):176–9.CrossRefPubMed
24.
25.
Wang DS, Louie JD, Kothary N, Shah RP, Sze DY. Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization. J Vascul Interv Radiol JVIR. 2013;24(4):596–600.CrossRef
26.
27.
Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123(2):224–7.CrossRefPubMed
28.
29.
Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. Journal of vascular and interventional radiology: JVIR. 2007;18(4):553–61; quiz 62.
30.
Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38(8):4824–45.CrossRefPubMed
31.
Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC. Development and evaluation of an improved quantitative (90)Y bremsstrahlung SPECT method. Med Phys. 2012;39(5):2346–58.CrossRefPubMedPubMedCentral
Metadata
Title
90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material
Authors
I. Kurilova
R. G. H. Beets-Tan
G. A. Ulaner
F. E. Boas
E. N. Petre
H. Yarmohammadi
E. Ziv
A. R. Deipolyi
L. A. Brody
M. Gonen
Constantinos T. Sofocleous
Publication date
01-09-2018
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 9/2018
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-018-1985-1

Other articles of this Issue 9/2018

CardioVascular and Interventional Radiology 9/2018 Go to the issue

Clinical Investigation

Transcatheter Arterial Embolization for Postoperative Bleeding Following Abdominal Surgery

Review

Portal Vein Embolization Utilizing N-Butyl Cyanoacrylate for Contralateral Lobe Hypertrophy Prior to Liver Resection: A Systematic Review and Meta-Analysis

Letter to the Editor

Inferior Vena Cava Filter Retrieval: A National Survey of Current Practice

Clinical Investigation

Transcatheter Arterial Embolization for Bleeding Peptic Ulcers: A Multicenter Study

Correction

Correction to: Radioembolization for Hepatocellular Carcinoma Arising in the Setting of a Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation)

Letter to the Editor

Another Case of Erratic Brain Embolism After Particle Embolization for a Giant Intrathoracic Solitary Fibrous Tumor